Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    20879881 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Conditions: Solid Tumors;   Brain Tumors;   Sarcoma;   Wilm's Tumor;   Rhabdomyosarcoma
Interventions: Biological: Recombinant human interleukin-15 (rhIL-15);   Biological: NK Cell Infusion
2 Recruiting Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: Isotretinoin;   Biological: Sargramostim;   Biological: Monoclonal Antibody Ch14.18;   Biological: Aldesleukin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Pharmacological Study
3 Recruiting A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With Non-neuroblastoma, GD2+ Solid Tumors
Conditions: Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Melanoma
Interventions: Biological: Anti-GD2-CAR engineered T cells;   Drug: AP1903;   Drug: Cyclophosphamide

Indicates status has not been verified in more than two years